

IN THE CLAIMS:

1-20.(Cancelled)

21.(Currently amended) A pharmaceutical composition comprising the antibody of any one of Claims 29-~~35~~ 33.

22-28.(Cancelled)

29.(Previously added) An antibody directed against an isolated IL-16 antagonist peptide consisting of CLLS (SEQ ID NO:2).

C 11 30.(Currently amended) An antibody directed against an isolated IL-16 antagonist peptide consisting of any one of WQCLLS (SEQ ID NO:4), WQALLS (SEQ ID NO:5), VVQVVA (SEQ ID NO:9) or VKQVVA (SEQ ID NO:11).

31.(Previously amended) An antibody directed against an isolated IL-16 antagonist peptide consisting of GMWQCLLS (SEQ ID NO:13).

32.(Previously added) An antibody directed against an isolated IL-16 antagonist peptide consisting of GMWQCLLSDSGQVLLE (SEQ ID NO:12).

33.(Previously added) An antibody directed against an isolated IL-16 antagonist peptide consisting of TGLWQCLLSEGD (SEQ ID NO:14).

34.(Withdrawn)

~~35.~~(Cancelled)